Transformation of severe congenital neutropenia to early acute lymphoblastic leukemia in a patient with HAX1 mutation and without G-CSF administration or receptor mutation Leukemia (2008) The diagnosis of severe congenital neutropenia (SCN) is clinically based on profound persistent neutropenia (absolute neutrophil count (ANC). We previously reported on an SCN patient who transformed to CALLA þ B-cell acute lymphoblastic leukemia (ALL). No constitutive mutation in the ELA2 gene or acquired mutation in the G-CSFR gene could be detected. 1 The female patient was the first-born child of parents who were second-degree relatives and she was diagnosed at the age of 5 months. There was no family history for an increased susceptibility to infection. The patient had a history of early onset of potentially life-threatening bacterial infection. Her white blood cell count was 6.3 Â 109 l À1 and differential count was 1% neutrophils (ANC: 0.063 Â 109 l À1 ), 30% monocytes, 63% lymphocytes and 6% eosinophils. Her bone marrow aspiration smear revealed apparent maturation arrest at promyelocyte stage. At 7 months of age, before initiation of granulocyte-colony stimulating factor (G-CSF) treatment, her peripheral blood revealed 20% lymphoblasts. Immunological and viral markers were normal and negative, respectively. Bone marrow and flow cytometric examination revealed 40-50% lymphoblasts, consistent with CALLA þ B-cell ALL (pre-B). The patient attained remission following induction therapy (St Jude Total XI study ALL protocol). She responded to G-CSF treatment but died due to septicemia during maintenance chemotherapy.
We hypothesized that HAX-1 gene mutation could be the cause of congenital neutropenia in this case and detect the mutation p.Q123fsX4 homozygously. Heterozygosity of the parents could be shown confirming SCN with autosomal recessive inheritance. This is the first report on a patient with secondary overt leukemia in SCN caused by HAX-1 gene mutation, indicating that a risk of malignant transformation is also associated with HAX-1 gene mutation.
Patients with SCN may transform to myelodysplastic syndrome (MDS) and acute myeloblastic leukemia. Most of these patients were treated with G-CSF. 2 In our patient, ALL developed without G-CSF treatment and no acquired G-CSFR mutation known to be associated with leukemogenesis in nearly 80% of SCN/leukemia was detectable. In light of the related literature and according to the rapid progression shown by our patient, the cause leading to malignant transformation in SCN is not yet clearly known. G-CSFR mutations were determined in three patients with HAX1 mutation, and one of them transformed to MDS. 3 There are also reports of two other SCN patients with G-CSFR mutation who transformed to ALL. 4, 5 We could show that SCN caused by HAX1 mutation can evolve to acute leukemia. Further studies will be necessary to determine the prevalence of malignant transformation and the mechanisms of leukemogenesis in this patient group.
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